Cargando…
Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study
We leveraged genetic variants associated with caffeine metabolism in the two-sample Mendelian randomization framework to investigate the effect of plasma caffeine levels on the risk of Alzheimer’s disease and Parkinson’s disease. Genetic association estimates for the outcomes were obtained from the...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102212/ https://www.ncbi.nlm.nih.gov/pubmed/35565667 http://dx.doi.org/10.3390/nu14091697 |
_version_ | 1784707276662112256 |
---|---|
author | Larsson, Susanna C. Woolf, Benjamin Gill, Dipender |
author_facet | Larsson, Susanna C. Woolf, Benjamin Gill, Dipender |
author_sort | Larsson, Susanna C. |
collection | PubMed |
description | We leveraged genetic variants associated with caffeine metabolism in the two-sample Mendelian randomization framework to investigate the effect of plasma caffeine levels on the risk of Alzheimer’s disease and Parkinson’s disease. Genetic association estimates for the outcomes were obtained from the International Genomics of Alzheimer’s Project, the International Parkinson’s Disease Genomics consortium, the FinnGen consortium, and the UK Biobank. Genetically predicted higher plasma caffeine levels were associated with a non-significant lower risk of Alzheimer’s disease (odds ratio 0.87; 95% confidence interval 0.76, 1.00; p = 0.056). A suggestive association was observed for genetically predicted higher plasma caffeine levels and lower risk of Parkinson’s disease in the FinnGen consortium. but not in the International Parkinson’s Disease Genomics consortium; no overall association was found (odds ratio 0.92; 95% confidence interval 0.77, 1.10; p = 0.347). This study found possible suggestive evidence of a protective role of caffeine in Alzheimer’s disease. The association between caffeine and Parkinson’s disease requires further study. |
format | Online Article Text |
id | pubmed-9102212 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91022122022-05-14 Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study Larsson, Susanna C. Woolf, Benjamin Gill, Dipender Nutrients Communication We leveraged genetic variants associated with caffeine metabolism in the two-sample Mendelian randomization framework to investigate the effect of plasma caffeine levels on the risk of Alzheimer’s disease and Parkinson’s disease. Genetic association estimates for the outcomes were obtained from the International Genomics of Alzheimer’s Project, the International Parkinson’s Disease Genomics consortium, the FinnGen consortium, and the UK Biobank. Genetically predicted higher plasma caffeine levels were associated with a non-significant lower risk of Alzheimer’s disease (odds ratio 0.87; 95% confidence interval 0.76, 1.00; p = 0.056). A suggestive association was observed for genetically predicted higher plasma caffeine levels and lower risk of Parkinson’s disease in the FinnGen consortium. but not in the International Parkinson’s Disease Genomics consortium; no overall association was found (odds ratio 0.92; 95% confidence interval 0.77, 1.10; p = 0.347). This study found possible suggestive evidence of a protective role of caffeine in Alzheimer’s disease. The association between caffeine and Parkinson’s disease requires further study. MDPI 2022-04-19 /pmc/articles/PMC9102212/ /pubmed/35565667 http://dx.doi.org/10.3390/nu14091697 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Larsson, Susanna C. Woolf, Benjamin Gill, Dipender Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study |
title | Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study |
title_full | Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study |
title_fullStr | Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study |
title_full_unstemmed | Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study |
title_short | Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study |
title_sort | plasma caffeine levels and risk of alzheimer’s disease and parkinson’s disease: mendelian randomization study |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102212/ https://www.ncbi.nlm.nih.gov/pubmed/35565667 http://dx.doi.org/10.3390/nu14091697 |
work_keys_str_mv | AT larssonsusannac plasmacaffeinelevelsandriskofalzheimersdiseaseandparkinsonsdiseasemendelianrandomizationstudy AT woolfbenjamin plasmacaffeinelevelsandriskofalzheimersdiseaseandparkinsonsdiseasemendelianrandomizationstudy AT gilldipender plasmacaffeinelevelsandriskofalzheimersdiseaseandparkinsonsdiseasemendelianrandomizationstudy |